Mouse Monoclonal PPP2R1B Antibody

+ +

•  

   
     All lanes : Anti-PPP2R1B Antibody at 1:4000 dilution Lane 1: Jurkat whole cell lysates Lane 2: human brain lysates Lane 3: mouse brain lysates Lane 4: mouse lung lysates Lane 5: rat brain lysates Lysates/proteins at 20 μg per lane. Secondary Goat Anti-mouse IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 66 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-2 OS (human bone osteosarcoma cell line) cells labeling PPP2R1B with P33130 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-mouse IgG   secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on U-2 OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing Jurkat cells stained with P33130 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P33130,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(NA168821)) at 1/400 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P33130 staining PPP2R1B in human spleen sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

**Background of PPP2R1B Antibody**

The PPP2R1B gene encodes the beta isoform of the regulatory subunit 1A (PR65β) of protein phosphatase 2A (PP2A), a critical serine/threonine phosphatase involved in cell signaling, growth, and apoptosis. PP2A functions as a tumor suppressor by regulating key pathways, such as Akt and MAPK, through dephosphorylation. PPP2R1B, located on chromosome 11q22. has been implicated in cancer due to frequent allelic loss or mutations in various malignancies, including lung, colon, and ovarian cancers. Antibodies targeting PPP2R1B are essential tools for studying its expression, localization, and interactions in cellular contexts.

PPP2R1B-specific antibodies are used in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to assess protein levels in tissues or cell lines. Reduced PPP2R1B expression, detected via these antibodies, correlates with tumor progression and poor prognosis, supporting its role as a tumor suppressor. Researchers also utilize these antibodies to explore PP2A complex assembly and dysfunction in diseases, including neurodegenerative disorders.

Commercial PPP2R1B antibodies vary in clonality, epitope specificity, and host species, requiring validation for target-specific applications. Understanding PPP2R1B’s regulatory mechanisms through such antibodies provides insights into therapeutic strategies targeting PP2A-related pathways in cancer and other pathologies.